These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16321863)

  • 1. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Leuk Lymphoma; 2006 Feb; 47(2):313-4. PubMed ID: 16321863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
    Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
    Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of the JAK2 V617F mutation on PRV-1 expression.
    Mnjoyan Z; Yoon D; Li J; Delhommeau F; Afshar-Kharghan V
    Haematologica; 2006 Mar; 91(3):411-2. PubMed ID: 16503546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of JAK2 V617F mutation in gastric cancers.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Acta Oncol; 2006; 45(2):222-3. PubMed ID: 16546874
    [No Abstract]   [Full Text] [Related]  

  • 7. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
    Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
    Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
    Marie I; Hervé F
    Rev Med Interne; 2006 Jun; 27(6):473-7. PubMed ID: 16631280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera and its molecular basis: an update.
    Chen G; Prchal JT
    Best Pract Res Clin Haematol; 2006; 19(3):387-97. PubMed ID: 16781479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
    Steensma DP
    J Mol Diagn; 2006 Sep; 8(4):397-411; quiz 526. PubMed ID: 16931578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
    Kralovics R; Teo SS; Li S; Theocharides A; Buser AS; Tichelli A; Skoda RC
    Blood; 2006 Aug; 108(4):1377-80. PubMed ID: 16675710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V; Darnige L; Gaussem P
    Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.
    Passamonti F; Rumi E; Pietra D; Della Porta MG; Boveri E; Pascutto C; Vanelli L; Arcaini L; Burcheri S; Malcovati L; Lazzarino M; Cazzola M
    Blood; 2006 May; 107(9):3676-82. PubMed ID: 16373657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.